The Hybrid Cell Vaccination Approach to Cancer lmmunotherapy

Trefzer, Uwe; Herberth, Gunda; Sterry, Wolfram; Walden, Peter

doi:10.1007/978-3-662-04183-3_10

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, DCs produced from culture in both types of media seem to be similar in their potential for inducing T‐cell proliferation. Despite the risk of xenosensitization against bovine antigens and the possible transfer of animal diseases such as BSE, FBS is still used in clinical studies for generating human DCs [38–40]. One reason for this is the allegedly higher allostimulatory capacity induced by xenogenic epitopes.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, in patients who have undergone several therapeutic regimens or might have other disease‐related inhibitory factors in their plasma, differentiation of DCs might not be feasible with our protocol. However, as recent clinical studies on patients with kidney cancer and malignant melanoma favour the use of allogeneic DCs from healthy volunteer donors hybridized with autologous tumour cells [39,40], our protocol might well serve as a convenient and cost‐efficient method for the generation of mature DCs.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The two initial clinical cancer immune therapy trials to test the HCV strategy were performed with patients suffering from malignant melanoma [171,172] or renal cell carcinoma [151,173]. The main objective of these initial clinical trials was to test the toxicity, feasibility and antitumor activity of this treatment.…”

Section: Clinical Experience With Hcvmentioning

confidence: 99%

Hybrid Cell Vaccination for Cancer Immune Therapy

Walden¹,

Stuhler²,

Trefzer³

2002

Cancer Immune Therapy

View full text Add to dashboard Cite

Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X L

Lundqvist

Nagata

Kiessling

et al. 2002

Cancer Immunology, Immunotherapy

View full text Add to dashboard Cite

The clinical use of dendritic cells (DC) as tumor vaccines is very much dependent on their survival potential. Members of the tumor necrosis factor (TNF) receptor superfamily and their ligands are involved in the regulation of cell death. Fas (CD95) is a representative protein that promotes apoptosis. The Bcl-2 family of proteins functions as an integrator of diverse pro- and anti-apoptotic signals. It has been found that DC maturation facilitates their survival, and thus has an anti-apoptotic function. However, little is known about the underlying mechanisms. We investigated the effects of TNF-alpha and lipopolysaccharide (LPS) on the expression of apoptotic molecules during differentiation and maturation of DC under serum-free conditions, and correlated this to the sensitivity to apoptosis by the Fas-mediated pathway. Indeed, DC activation effectively inhibited DC apoptosis, which was predominantly accompanied by the upregulation of Bcl-X(L) and to a lesser extent Bcl-2, while Bax and FLICE inhibitory protein (FLIP) remained unchanged. In contrast, in the presence of serum FLIP was also upregulated. We conclude that under serum-free conditions, Bcl-X(L) rather than FLIP plays the main role in protection against DC apoptosis.

show abstract

The Hybrid Cell Vaccination Approach to Cancer lmmunotherapy

Cited by 3 publications

References 19 publications

Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes

Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes

Hybrid Cell Vaccination for Cancer Immune Therapy

Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X L

Contact Info

Product

Resources

About